ABSTRACT
On the 20th of March 2020, triggered by the public health emergency declared, the Health Authorities in Madrid reported a legal instruction (Orden 371/2020) indicating the organization of a provisional hospital to admit patients with COVID-19 at the Trade Fair Institution (IFEMA). Several pharmacists working in the Pharmacy and Medical Devices Department of the Madrid Regional Health Service were called to manage the Pharmacy Department of the abovementioned hospital. Required permissions to set up a PD were here authorized urgently. Tackling human and material resources, and computer systems for drug purchase and electronic prescription, were some of the initial issues that hindered the pharmaceutical provision required for patients from the very day one. Once the purchase was assured, mainly by direct purchase from suppliers, drug dispensing up to 1,250 hospitalized patients (25 nursing units) and 8 ICU patients was taken on. Dispensing was carried out through either drug stocks in the nursing units or individual patient dispensing for certain drugs. Moreover, safety issues related to prescription were considered, and as the electronic prescription was implemented we attained 100% prescriptions review and validation. The constitution of a multidisciplinary Pharmacy and Therapeutics Committee let agree to a pharmacotherapy guide, pres cription protocols, therapeutic equivalences, interactions, and drug dispensing circuits. The Pharmacy Department strategy was to ensure a very quick response to basic tasks keeping the aim to offer a pharmaceutical care of the highest quality whenever possible. Working under a health emergency situation, with many uncertainties and continuous pressure was a plight. However, the spirit of collaboration in and out of the Pharmacy Department was aligned with the whole hospital motivation to offer the highest quality of healthcare. These were possibly the keys to allow caring for almost 4,000 patients during the 42 days that the hospital lasted.
El día 20 de marzo de 2020 la Consejería de Sanidad publicó una Orden (371/2020) para la apertura de un centro hospitalario provisional para atender a pacientes COVID-19 en la Institución Ferial de Madrid (IFEMA), por razón de emergencia sanitaria. Se dispuso un equipo de farmacéuticos de la Subdirección General de Farmacia y Productos Sanitarios para la apertura de un Servicio de Farmacia, que obtuvo la autorización correspondiente por el órgano competente, con carácter de urgencia. La gestión de recursos humanos, materiales y de herramientas informáticas para la adquisición y prescripción electrónica fueron unas de las primeras dificultades que se solaparon con el primer reto de garantizar la prestación farmacéutica a los pacientes que atendía el hospital desde el mismo día uno. Asegurada la adquisición, fundamentalmente mediante la compra directa a proveedores, se planteó la dispensación para un máximo de 1.250 pacientes de hospitalización (25 controles de enfermería) y una Unidad de Cuidados Intensivos de 8 pacientes; se establecieron botiquines en las unidades de enfermería y circuitos individualizados de dispensación para determinados medicamentos. A su vez, desde el primer momento se trabajó en la seguridad en la prescripción, llegando a la revisión y validación del 100% de los tratamientos, una vez instaurada la prescripción electrónica. La creación de una Comisión de Farmacia y Terapéutica multidisciplinar permitió consensuar la guía farmacoterapéutica, protocolos de prescripción, equivalencias terapéuticas, interacciones y circuitos de dispensación de medicamentos. La estrategia del Servicio de Farmacia se basó en asegurar una respuesta rápida en las funciones básicas, sin perder la visión de incorporar una atención farmacéutica de la máxima calidad posible a medida que iba siendo factible. A pesar de un escenario adverso, de incertidumbre y presión continuas por la emergencia sanitaria, se ha mantenido un espíritu de colaboración y contribución dentro y fuera del Servicio de Farmacia, alineado con un objetivo común de trabajo en equipo para brindar una atención sanitaria rápida y de la mayor calidad posible. Posiblemente éstas han sido las claves del éxito que han permitido atender a casi 4.000 pacientes en los 42 días de vida del hospital.
Subject(s)
Coronavirus Infections , Delivery of Health Care/organization & administration , Hospitals, Urban/organization & administration , Models, Theoretical , Pandemics , Pharmacy Service, Hospital/organization & administration , Pneumonia, Viral , Betacoronavirus , COVID-19 , Delivery of Health Care/legislation & jurisprudence , Delivery of Health Care/methods , Electronic Prescribing/standards , Facility Regulation and Control/legislation & jurisprudence , Forecasting , Health Facility Planning , Health Services Needs and Demand , Hospitalization , Hospitals, Urban/legislation & jurisprudence , Humans , Interdisciplinary Communication , Patient Safety , Pharmacy Service, Hospital/legislation & jurisprudence , Pharmacy and Therapeutics Committee/organization & administration , Quality Assurance, Health Care , SARS-CoV-2 , SpainABSTRACT
El día 20 de marzo de 2020 la Consejería de Sanidad publicó una Orden (371/2020) para la apertura de un centro hospitalario provisional para atender a pacientes COVID-19 en la Institución Ferial de Madrid (IFEMA), por razón de emergencia sanitaria. Se dispuso un equipo de farmacéuticos de la Subdirección General de Farmacia y Productos Sanitarios para la apertura de un Servicio de Farmacia, que obtuvo la autorización correspondiente por el órgano competente, con carácter de urgencia. La gestión de recursos humanos, materiales y de herramientas informáticas para la adquisición y prescripción electrónica fueron unas de las primeras dificultades que se solaparon con el primer reto de garantizar la prestación farmacéutica a los pacientes que atendía el hospital desde el mismo día uno. Asegurada la adquisición, fundamentalmente mediante la compra directa a proveedores, se planteó la dispensación para un máximo de 1.250 pacientes de hospitalización (25 controles de enfermería) y una Unidad de Cuidados Intensivos de 8 pacientes; se establecieron botiquines en las unidades de enfermería y circuitos individualizados de dispensación para determinados medicamentos. A su vez, desde el primer momento se trabajó en la seguridad en la prescripción, llegando a la revisión y validación del 100% de los tratamientos, una vez instaurada la prescripción electrónica. La creación de una omisión de Farmacia y Terapéutica multidisciplinar permitió consensuar la guía farmacoterapéutica, protocolos de prescripción, equivalencias terapéuticas, interacciones y circuitos de dispensación de medicamentos. La estrategia del Servicio de Farmacia se basó en asegurar una res-puesta rápida en las funciones básicas, sin perder la visión de incorporar una atención farmacéutica de la máxima calidad posible a medida que iba siendo factible. A pesar de un escenario adverso, de incertidumbre y presión continuas por la emergencia sanitaria, se ha mantenido un espíritu de colaboración y contribución dentro y fuera del Servicio de Farmacia, alineado con un objetivo común de trabajo en equipo para brindar una atención sanitaria rápida y de la mayor calidad posible. Posiblemente éstas han sido las claves del éxito que han permitido atender a casi 4.000 pacientes en los 42 días de vida del hospital
On the 20th of March 2020, triggered by the public health emergency declared, the Health Authorities in Madrid reported a legal instruction (Orden 371/2020) indicating the organization of a provisional hospital to admit patients with COVID-19 at the Trade Fair Institution (IFEMA).Several pharmacists working in the Pharmacy and Medical Devices Department of the Madrid Regional Health Service were called to manage the Pharmacy Department of the abovementioned hospital. Required permissions to set up a PD were here authorized urgently. Tackling human and material resources, and computer systems for drug purchase and electronic prescription, were some of the initial issues that hindered the pharmaceutical provision required for patients from the very day one. Once the purchase was assured, mainly by direct purchase from suppliers, drug dispensing up to 1,250 hospitalized patients (25 nursing units) and 8 ICU patients was taken on. Dispensing was carried out through either drug stocks in the nursing units or individual patient dispensing for certain drugs. Moreover, safety issues related to prescription were considered, and as the electronic prescription was implemented we attained 100% prescriptions review and validation. The constitution of a multidisciplinary Pharmacy and Therapeutics Committee let agree to a pharmacotherapy guide, prescription protocols, therapeutic equivalences, interactions, and drug dispensing circuits. The Pharmacy Department strategy was to ensure a very quick response to basic tasks keeping the aim to offer a pharmaceutical care of the highest quality whenever possible. Working under a health emergency situation, with many uncertainties and continuous pressure was a plight. However, the spirit of collaboration in and out of the Pharmacy Department was aligned with the whole hospital motivation to offer the highest quality of healthcare. These were possibly the keys to allow caring for almost 4,000 patients during the 42 days that the hospital lasted
Subject(s)
Humans , Coronavirus Infections , Delivery of Health Care/organization & administration , Hospitals, Urban/organization & administration , Pandemics , Pharmacy Service, Hospital/organization & administration , Betacoronavirus , Delivery of Health Care/legislation & jurisprudence , Electronic Prescribing/standards , Facility Regulation and Control/legislation & jurisprudence , Pharmacy Service, Hospital/legislation & jurisprudence , Pneumonia, Viral , Spain , Quality Assurance, Health Care , Pharmacy and Therapeutics Committee/organization & administration , Patient SafetySubject(s)
Antineoplastic Agents/therapeutic use , Blast Crisis/drug therapy , Fusion Proteins, bcr-abl/antagonists & inhibitors , Imidazoles/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Protein Kinase Inhibitors/therapeutic use , Pyridazines/therapeutic use , Antineoplastic Agents/adverse effects , Benzamides/pharmacology , Benzamides/therapeutic use , Dasatinib , Disease Progression , Drug Approval , Drug Resistance, Neoplasm/genetics , Drug Substitution , Female , Fusion Proteins, bcr-abl/genetics , Humans , Imatinib Mesylate , Imidazoles/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Middle Aged , Mutation, Missense , Piperazines/pharmacology , Piperazines/therapeutic use , Point Mutation , Pyridazines/adverse effects , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Thiazoles/pharmacology , Thiazoles/therapeutic useABSTRACT
This article presents a system for drug name recognition and classification in biomedical texts. The system combines information obtained by the Unified Medical Language System (UMLS) MetaMap Transfer (MMTx) program and nomenclature rules recommended by the World Health Organization (WHO) International Nonproprietary Names (INNs) Program to identify and classify pharmaceutical substances. Moreover, the system is able to detect possible candidates for drug names that have not been detected by MMTx program by applying these rules, achieving, in this way, a broader coverage. This work is the first step in a method for automatic detection of drug interactions from biomedical texts, a specific type of adverse drug event of special interest in patient safety.
Subject(s)
Pharmaceutical Preparations , Terminology as Topic , Unified Medical Language System/trends , Information Storage and Retrieval , Pharmaceutical Preparations/classificationABSTRACT
En 1999 la Academia Americana de Pediatría (AAP) y diferentes organizaciones de la salud lanzan una alerta sobre la presencia de derivados orgánicos de mercurio utilizados como conservantes en determinados medicamentos: vacunas, inmunoglobulinas y preparados oftalmológicos, debido a que han aparecido casos de neurotoxicidad tras la administración de estos preparados a niños pequeños. La información sobre los conservantes que contienen los medicamentos no siempre es homogénea y rara vez es tenida en cuenta a la hora de administrarlos. Métodos: Se realizó una revisión de las vacunas disponibles en el mercado español y de su contenido en derivados orgánicos del mercurio, principalmente timerosal. Resultados: Buena parte de las vacunas españolas contienen timerasal en dosis entre 0,025 y 0,05 mg, lo que ocasiona administraciones de 12 a 37 mcg de mercurio al seguir el calendario vacunal establecido. Conclusiones: La selección de determinadas marcas de vacunas puede reducir la administración de derivados mercuriales como excipientes de vacunas (AU)
In 1999 The American Academy of Pediatrics and different health organizations sent out an alert to the presence of organic derivatives of mercury used as preservatives in certain drugs, vaccines, immunoglobulins and ophthalmologic preparations, due to the fact that cases of neurotoxicity have appeared after the administration of these preparations in young children. The information on the preservatives that the drugs contain is not always homogeneous and is rarely taken into account when they are administered. Methods: A review of the available vaccines in the Spanish market was carried out as to their contents of organic mercury derivates, mainly thimerosal. Conclusions: The selection of determined brand names of vaccine could reduce the administration of mercurial derivates as excipient of vaccines (AU)